Sugi Predict

Sugi Predict / Compounds / SCHEMBL2803084

SCHEMBL2803084

SCHEMBL2803084

CC(C)Oc1ccc(C[C@H](N)C(=O)O)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.60
▸ SLC7A5 Q01650 3/20 0.59
▸ PTGS1 P23219 3/20 0.58
▸ ALPI P09923 1/20 0.58
▸ PKM P14618 1/20 0.58
▸ XIAP P98170 1/20 0.58
▸ PTPN1 P18031 1/20 0.57
▸ ITGB3 P05106 1/20 0.56
▸ ITGA2B P08514 1/20 0.56
▸ ACACB O00763 2/20 0.52
▸ KMT2A Q03164 1/20 0.51
▸ TPH1 P17752 3/20 0.50
▸ HIF1A Q16665 3/20 0.50
▸ KDM4E B2RXH2 2/20 0.50
▸ ALOX15 P16050 2/20 0.50
▸ TDP1 Q9NUW8 2/20 0.50
▸ GRB2 P62993 1/20 0.50
▸ PARP10 Q53GL7 1/20 0.50
▸ USP2 O75604 1/20 0.50
▸ EGFR P00533 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19759402 1.00 POLB (0.60) POLBSLC7A5PTGS1ALPIPKM
SCHEMBL31370032 0.95 POLB (0.55) POLBSLC7A5PTGS1ALPIPKM
SCHEMBL31688665 0.89 SLC7A5 (0.57) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL31688893 0.89 SLC7A5 (0.57) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL28219939 0.88 POLB (0.48) POLBSLC7A5PTGS1ALPIPKM
SCHEMBL27827419 0.87 PTPN1 (0.58) POLBSLC7A5PTGS1ALPIPKM
SCHEMBL7360168 0.85 SLC7A5 (0.61) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL7360179 0.85 SLC7A5 (0.61) SLC7A5PTGS1ALPIPKMXIAP
Hydrochloric Acid SCHEMBL16816053 0.84 ACACB (0.54) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL5808756 0.84 SLC7A5 (0.53) SLC7A5PTGS1ALPIPKMXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4211146-B1 SYNTHETIC CYCLIC PEPTIDE MIMETICS UNIV BAR ILAN (IL) 2026-05-20 — — EP claimed
US-12616760-B2 Synthetic cyclic peptide mimetics BAR ILAN UNIVERSITY (IL) 2026-05-05 — — US claimed
WO-2024241086-A1 PEGYLATED BOVINE INTERFERON LAMBDA AND METHODS OF USE THEREOF AMBRX, INC. (US) 2024-11-28 — — WO claimed
US-20240316225-A1 SYNTHETIC CYCLIC PEPTIDE MIMETICS BAR ILAN UNIVERSITY (IL) 2024-09-26 — — US claimed
WO-2024178310-A1 TROP2-DIRECTED ANTIBODY-DRUG CONJUGATES AND USES THEREOF AMBRX, INC. (US) 2024-08-29 — — WO claimed
CN-113481228-B Microbial unnatural amino acid introducing system and construction method 中国药科大学 2024-07-19 — — CN claimed
EP-4211146-A1 SYNTHETIC CYCLIC PEPTIDE MIMETICS Bar Ilan University (IL) 2023-07-19 — — EP claimed
WO-2022054062-A1 SYNTHETIC CYCLIC PEPTIDE MIMETICS BAR ILAN UNIVERSITY (IL) 2022-03-17 — — WO claimed
CN-113481228-A Microorganism unnatural amino acid introduction system and construction method 中国药科大学 2021-10-08 — — CN claimed
EP-4211146-B1 SYNTHETIC CYCLIC PEPTIDE MIMETICS UNIV BAR ILAN (IL) 2026-05-20 — — EP disclosed
US-12616760-B2 Synthetic cyclic peptide mimetics BAR ILAN UNIVERSITY (IL) 2026-05-05 — — US disclosed
WO-2024241086-A1 PEGYLATED BOVINE INTERFERON LAMBDA AND METHODS OF USE THEREOF AMBRX, INC. (US) 2024-11-28 — — WO disclosed
WO-2024215515-A1 DRUG LINKERS AND ANTIBODY CONJUGATES THEREOF AMBRX, INC. (US) 2024-10-17 — — WO disclosed
US-20240316225-A1 SYNTHETIC CYCLIC PEPTIDE MIMETICS BAR ILAN UNIVERSITY (IL) 2024-09-26 — — US disclosed
US-20130296327-A1 SUBSTITUTED HETEROCYLIC COMPOUNDS INCYTE CORPORATION 2013-11-07 — — US disclosed
US-8481732-B2 Substituted heterocyclic compounds INCYTE CORPORATION (US) 2013-07-09 — — US disclosed
US-8354454-B2 Prodrugs of oxazolidinone CETP inhibitors MERCK SHARP & DOHME CORP. (US) 2013-01-15 — — US disclosed
US-20110218177-A1 PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS MERCK SHARP & DOHME LLC 2011-09-08 — — US disclosed
US-20100240671-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS INCYTE CORPORATION (US) 2010-09-23 — — US disclosed
WO-2010108059-A1 SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTAGONISTS OF THE HISTAMINE H4 RECEPTOR INCYTE CORPORATION (US) 2010-09-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130296327-A1 SUBSTITUTED HETEROCYLIC COMPOUNDS HRH4, HRH2, HRH1 POLB 3768/4885SLC7A5 1102/4885PTGS1 63/4885
US-12616760-B2 Synthetic cyclic peptide mimetics TPX2, IAPP, HAX1 POLB 4286/4885SLC7A5 326/4885PTGS1 4267/4885
US-20110218177-A1 PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS CETP, SLCO2B1, OXA1L POLB 210/4885SLC7A5 1089/4885PTGS1 2136/4885
US-20240316225-A1 SYNTHETIC CYCLIC PEPTIDE MIMETICS IAPP, QPCTL, DNPEP POLB 3353/4885SLC7A5 300/4885PTGS1 4044/4885
US-20100240671-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS HRH4, HRH2, HRH1 POLB 3084/4885SLC7A5 918/4885PTGS1 100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.